(Reuters) – German chemicals group Evonik Industries on Thursday reported adjusted core profit for the third quarter broadly in-line with analysts’ estimates, citing increased demand across all of its divisions and higher pricing.
The company, which makes ingredients for products ranging from animal feed and diapers to ingredients for Pfizer/BioNTech’s COVID-19 vaccine, reported adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) of 645 million euros ($747.23 million) in the third quarter, up 24% and slightly above analysts’ forecast of 641.1 million euros in a company-provided poll.
($1 = 0.8632 euros)
(Reporting by Karol Badohal and Bartosz Dabrowski in Gdansk. Editing by Jane Merriman)
